You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.
The tests have received coverage decisions from a number of Blue Cross Blue Shield plans this year including ones in California and New Jersey.
The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.
This week's news about SeraCare Life Sciences, Human Longevity Clinical Labs, CareDx, Interpace Diagnostics, Boston Scientific, OpGen, and MDxHealth's SelectMDx.
The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.
Under the new agreement, physicians can order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis.
The revenue growth was primarily driven by the company's two thyroid tests, which have been steadily gaining payor coverage.
Interpace said that its two thyroid tests are now covered for over 280 million patients nationwide including Medicare, Medicare Advantage, and national and regional health plans.
The payor has agreed to cover Interpace's ThyGenX and ThyraMir, for thyroid nodules deemed indeterminate by standard cytopathological analysis.
Interpace can now offer the new service alone or in conjunction with ThyGenX next-generation sequencing oncogene panel in New York.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.